Stocktoria
NovoCure Ltd NVCR
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2015-10-01
NovoCure Ltd financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $655.4M | $605.2M | $509.3M | $537.8M | $535.0M |
| Gross profit | $488.5M | $468.0M | $381.1M | $423.0M | $420.2M |
| R&D expense | $224.5M | $209.6M | $223.1M | $206.1M | $201.3M |
| Operating income | -$153.8M | -$170.5M | -$232.9M | -$89.5M | -$44.3M |
| Interest expense | $22.2M | $11.7M | $4.9M | $8.1M | $8.8M |
| Income tax | -$23,000 | $37.5M | $15.3M | $10.7M | $6.3M |
| Net income | -$136.2M | -$168.6M | -$207.0M | -$92.5M | -$58.4M |
| EPS (diluted) | $-1.22 | $-1.56 | $-1.95 | $-0.88 | $-0.56 |
| Operating cash flow | -$49.0M | -$26.4M | -$73.3M | $30.8M | $82.8M |
| Free cash flow | -$75.7M | -$69.2M | -$100.4M | $9.4M | $58.6M |
| Cash & equivalents | $93.5M | $163.8M | $240.8M | $115.3M | $208.8M |
| Inventory | $41.1M | $35.1M | $38.2M | $29.4M | $24.4M |
| Total assets | $804.3M | $1.2B | $1.1B | $1.2B | $1.1B |
| Total liabilities | $463.9M | $880.6M | $783.6M | $750.5M | $729.0M |
| Shareholders' equity | $340.5M | $360.2M | $362.5M | $441.2M | $410.5M |
Source: SEC EDGAR filings · CIK 0001645113 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.